Is there a link between BPH and prostate cancer?

Practitioner

Volumn 256, Issue 1750, 2012, Pages 13-16

  Chang, R T M ^a   Kirby, Roger ^b   Challacombe, B J ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Prostate Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CONFERENCE PAPER; DIGITAL RECTAL EXAMINATION; HUMAN; MALE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; RISK FACTOR;

DIGITAL RECTAL EXAMINATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84860639194     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med2002;347:839-840 (Pubitemid 34988344)
2. Verhamme K, Dieleman J, Bleumink G et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project. Eur Urol 2002;42:323-328 (Pubitemid 35175791)
3. Chapple R. The Total Approach in Lower UrinaryTract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management: Introduction and Conclusions. European Urology Supplements2003;12(7):1-5
4. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract2004;54(505):617-21 (Pubitemid 39117573)
5. Roobol MJ, Steyerberg EW, Kranse R et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85
6. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Fam Pract 1999;16(6):621-6 (Pubitemid 30000182)
7. Harvey P, Basuita A, Endersby D et al. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 2009;Sep 10:9-14
8. European Association of Urology. Guidelines on Benign Prostatic Hyperplasia. 2006. www.uroweb.org/fileadmin/user-upload/Guidelines/11%20BPH.pdf
9. Rabbani F, Stroumbakis N, Kava BR et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159(4):1247-1250 (Pubitemid 28172807)
10. Johns LE, Houlston RS. A systematic review and metaanalysis of familial prostate cancer risk. BJU Int2003: 91(9):789-794 (Pubitemid 36724060)
11. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 2004;101(Suppl 10):2371-490 (Pubitemid 39505434)
12. 12Brandt A, Bermejo JL, Sundquist J et al. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 2010; 58:275-280
13. Ørsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 2011;60(4):691-8
14. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215-24 (Pubitemid 36859473)
15. Thompson IM, Tangen CM, Goodman PJ et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177(5):1749-52 (Pubitemid 46560657)
16. Kulkarni GS, Al-Azab R, Lockwood G et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006;175(2):505-9 (Pubitemid 43067339)
17. Cohen YC, Liu KS, Heyden NL et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst2007;99(18):1366-74 (Pubitemid 351767189)
18. Redman MR, Tangen C, Goodman PJ et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modelling approach.Cancer Prev Res 2008;1:174-81
19. 19Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother2004;5(6):1279-85 (Pubitemid 38885789)